Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Seeing some doubt here and on other sites
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(199)
•••
Post by Red~Oneon Jan 19, 2022 9:47am
202 Views
Post# 34332206

RE:RE:Seeing some doubt here and on other sites

RE:RE:Seeing some doubt here and on other sitesI see you brought some help from the private site, howzit goin'?

Clas is not a biotech , they have no product.

They (BOB) is not developing N.O. tech , his company is stalled.

One of the competition that you allude to is already selling their product OTC in Israel, Thailand and soon in a new market with populatin of 250 million souls.

Another company you alluded to is selling NO generating products including a lozenge that dissolves on your tongue while generating NO that you swallow. That company has donated $790,000 US worth of their Nitric Oxide product to Nepal for the covid crisis.

"See Don run. run, run, run. Escalator down. Down, down, down. Mexicans bad. Bad, bad, bad. Build a wall." Hey D



 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities